View on Pubmed.gov 28053053 | View on doi.org 10.1136/gutjnl-...
Acute-on-chronic liver failure: an update.
- Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
- Liver Unit, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
- Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Centro d'Investigaciones Biomedicas en Red, enfermedades Hepaticas y Digestivas (CIBEReHD), Barcelona, Spain.
- Inserm, U1149, Centre de Recerche sur l'inflammation (CRI), Paris, France.
- Faculté de Médicine, Université Paris Diderot, Paris, France.
- Départment Hospitalo-Universitaire (DHU) UNITY, Service d'Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France.
- Laboratoire d'Excellence (Labex) Inflamex, CUE Sorbonne Paris Cité, Paris, France.
- European Foundation for the Study of Chronic Liver Failure (EF-CLIF), Barcelona, Spain.
Abstract
Acute-on-chronic liver failure (ACLF) is a syndrome characterised by acute decompensation of chronic liver disease associated with organ failures and high short-term mortality. Alcohol and chronic viral hepatitis are the most common underlying liver diseases. Up to 40%-50% of the cases of ACLF have no identifiable trigger; in the remaining patients, sepsis, active alcoholism and relapse of chronic viral hepatitis are the most common reported precipitating factors. An excessive systemic inflammatory response seems to play a crucial role in the development of ACLF. Using a liver-adapted sequential organ assessment failure score, it is possible to triage and prognosticate the outcome of patients with ACLF. The course of ACLF is dynamic and changes over the course of hospital admission. Most of the patients will have a clear prognosis between day 3 and 7 of hospital admission and clinical decisions such as evaluation for liver transplant or discussion over goals of care could be tailored using clinical scores. Bioartificial liver support systems, granulocyte-colony stimulating factors or stem-cell transplant are in the horizon of medical care of this patient population; however, data are too premature to implement them as standard of care.
References
Hepatology. 2015 Jul;62(1):243-52
Hepatology. 2013 Mar;57(3):1153-62
Hepatology. 2016 Oct;64(4):1249-64
JAMA. 2003 Jan 8;289(2):217-22
Cited by 547 citations (total)
Journal Article
The role of prophylactic antibiotics in hepatitis B virus-related acute-on-chronic liver failure patients at risk of bacterial infection: a retrospective study.
Electronic publication date April 2, 2021
Xiao-Qin Liu [...] Yu-Xian Huang et al.
BACKGROUND
Acute-on-chronic liver failure (ACLF) is characterized by an excessive systemic inflammatory response and organ failure and has high mortality. Bacterial...
Journal Article
Granulocyte Colony-Stimulating Factor Use in Decompensated Cirrhosis: Lack of Survival Benefit.
Electronic publication date March 20, 2020
Cyriac A Philips [...] Solomon K John et al.
BACKGROUND
Granulocyte colony-stimulating factor (GCSF) has been utilized in decompensated cirrhosis (DC) for improving transplant-free survival (TFS). Data from multiple centers...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Copyright
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.